SCHEDULE 13G/A: Citadel Entities Disclose 2.0% Passive Stake in Ventyx Biosciences
Schedule 13G Filing
Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin have jointly disclosed a 2.0% beneficial ownership stake in Ventyx Biosciences, Inc. as of March 31, 2025.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 1,393,033 shares of Ventyx Biosciences, Inc. Common Stock, representing 2.0% of the outstanding shares.
- Citadel Securities LLC beneficially owns 16,263 shares, representing 0.0% of the outstanding shares.
- Citadel Securities Group LP and Citadel Securities GP LLC collectively beneficially own 16,568 shares, representing 0.0% of the outstanding shares.
- Kenneth Griffin, through his controlling interests in the Citadel entities, beneficially owns an aggregate of 1,409,601 shares, also representing 2.0% of the outstanding shares.
- All reported beneficial ownership is characterized by shared voting and shared dispositive power, with no sole voting or dispositive power held by any reporting person.
- The percentages are based on 71,130,054 shares outstanding as of February 24, 2025, as reported in Ventyx Biosciences' Form 10-K filed on February 27, 2025.
- The filing is an Amendment No. 4 to Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook. It is a standard regulatory filing.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant institutional investment by Citadel entities in Ventyx Biosciences, Inc., a common occurrence in the public markets where large investment firms take passive stakes in publicly traded companies. It does not provide specific insights into broader industry trends but highlights institutional interest in the biotechnology or pharmaceutical sector, where Ventyx Biosciences likely operates.
Stakeholder Impact
- Shareholders: The disclosure of a significant passive stake by Citadel entities may be viewed positively by existing shareholders as it indicates institutional confidence and liquidity in the stock. It could also signal increased scrutiny or interest from other institutional investors.
- Company Management: Awareness of a significant institutional holder like Citadel may influence management's focus on shareholder value, although the filing explicitly states the stake is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2025-02-24 | Date as of which 71,130,054 shares of Ventyx Biosciences, Inc. were outstanding, according to the issuer's Form 10-K. |
| 2025-02-27 | Date Ventyx Biosciences, Inc. filed its Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-05-15 | Date of filing of this Schedule 13G statement. |
Keywords
Ventyx Biosciences, Citadel, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Holding, Passive Investment, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.